Page last updated: 2024-10-28

miltefosine and Lung Neoplasms

miltefosine has been researched along with Lung Neoplasms in 4 studies

miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.

Lung Neoplasms: Tumors or cancer of the LUNG.

Research Excerpts

ExcerptRelevanceReference
" In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed."2.67Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pronk, LC1
Planting, AS1
Oosterom, R1
Drogendijk, TE1
Stoter, G2
Verweij, J2
Theischen, M1
Bornfeld, N1
Becher, R1
Kellner, U1
Wessing, A1
Planting, A1
van der Burg, M1
Bishop, FE1
Dive, C1
Freeman, S1
Gescher, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705]Phase 3437 participants (Actual)Interventional2006-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete Clinical Response

"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment

Interventionparticipants (Number)
Miltefosine85
Glucantime®103
Thermotherapy86

Failure

At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment

Interventionparticipants (Number)
Miltefosine34
Glucantime®14
Thermotherapy42

Recurrence

Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment

InterventionParticipants (Number)
Miltefosine3
Glucantime®4
Thermotherapy6

Trials

3 trials available for miltefosine and Lung Neoplasms

ArticleYear
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma,

1994
Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium.
    German journal of ophthalmology, 1993, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Electrooculography; Electroretinography

1993
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore

1992

Other Studies

1 other study available for miltefosine and Lung Neoplasms

ArticleYear
Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Membrane; Cell Survival; Dose-Response Relation

1992